Cargando…
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
BACKGROUND: Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8(+) T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target to deliver antigens. cDC1s uniquely express XCR1, a...
Autores principales: | Le Gall, Camille, Cammarata, Anna, de Haas, Lukas, Ramos-Tomillero, Iván, Cuenca-Escalona, Jorge, Schouren, Kayleigh, Wijfjes, Zacharias, Becker, Anouk M D, Bödder, Johanna, Dölen, Yusuf, de Vries, I Jolanda M, Figdor, Carl G, Flórez-Grau, Georgina, Verdoes, Martijn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014073/ https://www.ncbi.nlm.nih.gov/pubmed/35428705 http://dx.doi.org/10.1136/jitc-2021-004309 |
Ejemplares similares
-
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020) -
Controlling
Antigen Fate in Therapeutic Cancer Vaccines
by Targeting Dendritic Cell Receptors
por: Wijfjes, Zacharias, et al.
Publicado: (2023) -
NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013) -
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
por: Camisaschi, Chiara, et al.
Publicado: (2018) -
Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)